We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
ANI Pharmaceuticals
ANIP
$1.8B
| $796K | ﹤0.01% |
16,073
+3,725
| +30% | +$209K |
|
2027
HCI Group
HCI
$2.23B
| $796K | ﹤0.01% |
17,455
-12,237
| -41% | -$538K |
|
2028
OneSpan
OSPN
$574M
| $793K | ﹤0.01% |
58,753
+16,496
| +39% | +$232K |
|
|
BRSS
2029
DELISTED
Global Brass & Copper Hldgs, Inc
BRSS
| $793K | ﹤0.01% |
23,048
+855
| +4% | +$29.1K |
|
2030
Corcept Therapeutics
CORT
$12.4B
| $791K | ﹤0.01% |
72,178
+2,492
| +4% | +$21.9K |
|
2031
Douglas Dynamics
PLOW
$1.02B
| $788K | ﹤0.01% |
25,703
+1,297
| +5% | +$42.1K |
|
|
PSTB
2032
DELISTED
Park Sterling Corp.
PSTB
| $787K | ﹤0.01% |
63,968
+3,493
| +6% | +$40.5K |
|
|
THR
2033
DELISTED
Thermon Group Holdings
THR
| $783K | ﹤0.01% |
37,549
+949
| +3% | +$19K |
|
2034
NN Inc
NNBR
$255M
| $782K | ﹤0.01% |
31,023
+603
| +2% | +$12.6K |
|
2035
Stride
LRN
$3.41B
| $781K | ﹤0.01% |
40,767
+1,148
| +3% | +$20.8K |
|
|
SN
2036
DELISTED
Sanchez Energy Corporation
SN
| $781K | ﹤0.01% |
81,844
+18,246
| +29% | +$204K |
|
|
INOV
2037
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $780K | ﹤0.01% |
61,919
+4,218
| +7% | +$48.9K |
|
2038
Astronics
ATRO
$3.43B
| $778K | ﹤0.01% |
33,838
+4,426
| +15% | +$104K |
|
2039
Daktronics
DAKT
$955M
| $777K | ﹤0.01% |
82,248
+20,468
| +33% | +$202K |
|
2040
Kforce
KFRC
$1.02B
| $775K | ﹤0.01% |
32,646
+1,208
| +4% | +$28.8K |
|
2041
Movado Group
MOV
$849M
| $774K | ﹤0.01% |
31,032
+7,512
| +32% | +$190K |
|
|
IVC
2042
DELISTED
Invacare Corporation
IVC
| $772K | ﹤0.01% |
64,888
+17,364
| +37% | +$208K |
|
|
BMTC
2043
DELISTED
Bryn Mawr Bank Corp
BMTC
| $771K | ﹤0.01% |
19,519
+766
| +4% | +$31K |
|
|
PIR
2044
DELISTED
Pier 1 Imports, Inc.
PIR
| $768K | ﹤0.01% |
5,366
+32
| +0.6% | +$4.69K |
|
2045
Chegg
CHGG
$110M
| $767K | ﹤0.01% |
90,909
+2,973
| +3% | +$22.9K |
|
|
ANH
2046
DELISTED
Anworth Mortgage Asset Corporation
ANH
| $767K | ﹤0.01% |
138,260
+4,720
| +4% | +$25.2K |
|
2047
Greenlight Captial
GLRE
$552M
| $766K | ﹤0.01% |
34,654
+1,857
| +6% | +$42.1K |
|
2048
QuidelOrtho
QDEL
$1.14B
| $766K | ﹤0.01% |
33,836
+1,268
| +4% | +$26.2K |
|
2049
Coherus Oncology
CHRS
$217M
| $765K | ﹤0.01% |
36,177
+3,969
| +12% | +$97.6K |
|
|
FBC
2050
DELISTED
Flagstar Bancorp, Inc. New
FBC
| $765K | ﹤0.01% |
27,134
+1,637
| +6% | +$44.5K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.